Publication details

Neuroleptický maligní syndrom a jeho řešení v klinické praxi z perspektivy současných doporučených postupů

Title in English Neuroleptic malignant syndrome and its management in clinical practice from the perspective of current guidelines


Year of publication 2021
Type Article in Periodical
Magazine / Source Česká a slovenská psychiatrie
MU Faculty or unit

Faculty of Medicine

Keywords neuroleptic malignant syndrome; prevalence; guidelines; benzodiazepines; bromocriptine; dantrolene; electroconvulsive therapy
Description The paper deals with recent aspects of diagnosis and treatment of neuroleptic malignant syndrome (NMS). NMS is an antipsychotic-induced, life-threatening condition, characterized by hyperpyrexia, muscle rigidity, qualitative alteration of consciousness and autonomic nervous system dys-regulation. NMS prevalence and mortality rates have declined over the past 30 years, most likely due to early recognition of the syndrome and appropriate intervention. Recent reports suggest a prevalence of 0.02-0.03%, and 5.6% mortality. Treatment includes withdrawal of the offending dopamine antagonist, supportive care and may include the use of specific pharmacotherapies (benzodiazepines, bromocriptine, amentadine, dantrolene) and electroconvulsive therapy. Nonetheless, clinicians, especially primary care clinicians who are using antipsychotics more often for adjunctive treatments, must be cognizant of this syndrome.

You are running an old browser version. We recommend updating your browser to its latest version.

More info